Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ROS1 wild-type
i
Other names:
ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6098
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ROS1 wild-type
Lung Non-Small Cell Squamous Cancer
ROS1 wild-type
Lung Non-Small Cell Squamous Cancer
cemiplimab-rwlc
Sensitive: B - Late Trials
cemiplimab-rwlc
Sensitive
:
B
cemiplimab-rwlc
Sensitive: B - Late Trials
cemiplimab-rwlc
Sensitive
:
B
ROS1 wild-type
Lung Non-Squamous Non-Small Cell Cancer
ROS1 wild-type
Lung Non-Squamous Non-Small Cell Cancer
cemiplimab-rwlc
Sensitive: B - Late Trials
cemiplimab-rwlc
Sensitive
:
B
cemiplimab-rwlc
Sensitive: B - Late Trials
cemiplimab-rwlc
Sensitive
:
B
ROS1 wild-type
Lung Non-Squamous Non-Small Cell Cancer
ROS1 wild-type
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + bevacizumab
Sensitive: B - Late Trials
nivolumab + bevacizumab
Sensitive
:
B
nivolumab + bevacizumab
Sensitive: B - Late Trials
nivolumab + bevacizumab
Sensitive
:
B
ROS1 wild-type
Non Small Cell Lung Cancer
ROS1 wild-type
Non Small Cell Lung Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
ROS1 wild-type
Non Small Cell Lung Cancer
ROS1 wild-type
Non Small Cell Lung Cancer
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
ROS1 wild-type
Non Small Cell Lung Cancer
ROS1 wild-type
Non Small Cell Lung Cancer
tislelizumab-jsgr
Sensitive: C3 – Early Trials
tislelizumab-jsgr
Sensitive
:
C3
tislelizumab-jsgr
Sensitive: C3 – Early Trials
tislelizumab-jsgr
Sensitive
:
C3
ROS1 wild-type
Non Small Cell Lung Cancer
ROS1 wild-type
Non Small Cell Lung Cancer
anlotinib + cadonilimab
Sensitive: C3 – Early Trials
anlotinib + cadonilimab
Sensitive
:
C3
anlotinib + cadonilimab
Sensitive: C3 – Early Trials
anlotinib + cadonilimab
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.